Abbott’s Lingo Biowearable For Consumers Debuts In The UK As Libre Momentum Continues
Executive Summary
Abbott launched its first biowearable for consumers in the UK with plans to expand in Europe and the US. Analysts are optimistic about continued growth of Libre FreeStyle amid drivers such as CGM adoption by non-insulin users, expected 15-day sensor, streaming capability and integration with Tandem insulin pump.
You may also be interested in...
Are GLP-1 Major Threat To The Insulin Delivery Tech Market?
A small scale study has indicated that GLP-1 agonists could restore normal HbA1c levels in type I diabetics. This therapy could be a huge step forward for the treatment of this chronic disease if this benefit is shown in larger studies.
Dexcom Tries To Close Gap On Abbott in CGM
The continuous glucose monitoring space is expanding fast enough to accommodate two big players. Both Dexcom and Abbott recorded double-digit sales growth during the last quarter.
Exec Chat: Tandem CEO Sheridan On Coming Mobi Pump, New Algorithms, And Taking Share From Medtronic
In this second of a series of Exec Chats with leaders at major diabetes companies presenting at ADA’s Scientific Sessions 2023, CEO John Sheridan provides a tour of Tandem’s next-gen innovations and the competitive landscape.